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Peer review under responsibility of Saudi Ophthalmological Society, King Saud University.Ali M. Al-Halafi, MD, FRCS ⇑AbstractThe basic concept for the application of vital dyes during vitreoretinal surgery is to assist in highlighting preretinal membranes and
tissues which are very thin and semitransparent and thus difficult to detect. The vital dyes may be classified according to different
criteria, where the most commonly applied includes chemical classification. In ophthalmic surgery, vital dyes are widely used in
cataract and vitreoretinal surgery. The vital dyes, indocyanine green, infracyanine green, and brilliant blue stain the internal limiting
membrane, and trypan blue and triamcinolone acetonide help to visualize epiretinal membranes and vitreous, respectively. This
review exhibits the current literature regarding the properties of vital dyes, techniques of application, indications, and toxicities
during vitreoretinal surgery and, also suggests that the field of chromovitrectomy represents an expanding area of research.
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The field of vitreoretinal surgery has grown over the last
several decades. Scientific advances improved our under-
standing of disease pathology and new surgical adjuncts
and techniques have decreased surgical time and increased
success rate. One of the innovations in vitreoretinal surgery
over the past 10 years has been the introduction of vital dyes
to improve the visualization of preretinal tissues and mem-
branes.1–4
The term ‘‘chromovitrectomy’’ refers to the use of vital
dyes during vitreoretinal surgery to assist in the identification
of preretinal tissues and membranes.5 In 2000, the modern
approach was first introduced, when the dye indocyanine
green (ICG) was used to stain the thin semitransparent
internal limiting membrane (ILM), and it is currently the most
commonly used surgical dye in ophthalmology. However,
over the past few years, controversial evidence has accumu-
lated indicating that these dyes may have harmful effects.
Following initial experience with ICG, clinical and experimen-
tal studies demonstrated signs of the retinal toxicity of ICG,which stimulated research on alternative dyes for chromovitr-
ectomy. Some additional alternative biostains, including
trypan blue (TB), or brilliant blue (BriB), and patent blue
(PB), have been added to the surgical collection for
chromovitrectomy.6 This review presents the latest data on
chromovitrectomy in regard to the biochemical properties,
indications, and clinical experience with various vital dyes
available for chromovitrectomy.Biochemical pharmacology
Vital staining refers to the coloration of living cells or tis-
sues. Dyes are organic molecules containing chromophores.
A chromophore is the part of a molecule responsible for its
color.7
The staining agents may be classified according to the
chemical classification. Some of the groups of dyes already
used in chromovitrectomy are: (1) azo dyes; (2) arylmethane
dyes; (3) cyanine dyes; (4) xanthene dyes; and (5) colored
corticosteroids.e:
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Figure 1. Vitreal injection of indocyanine green (ICG) to stain Internal
limiting membrane (ILM) in maculer hole surgery.
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nitrogen in the azo form of –N@N– in their structure. TB is
an anionic hydrophilic azo dye which has the molecular for-
mula C34H24N6Na4O14S4 and a molecular weight of 960 Da.
TB is so-called because it can kill trypanosomes, the parasites
that cause sleeping sickness.8 TB crosses the cell membranes
of dead cells only, because of that stains dead tissues/cells
blue. In ophthalmology, TB has in a preferential manner
affinity for the epiretinal membrane (ERM).9–13 TB may be
commercially available at a concentration of 0.15% for vitre-
oretinal surgery, called Membrane Blue (DORC International,
Zuidland, Netherlands).
Cyanine dyes are a class of dyes containing a –CH@ group
linking two heterocyclic rings containing nitrogen. The cya-
nine agent has amphiphilic properties and thereby binds to
both cellular and acellular elements in living tissues. ICG is
a tricarbocyanine anionic vital dye with a molecular formula
of C43H47N2NaO6S2 and a molecular weight of 775 Da. The
sterile hydrophilic powder represents a very useful contrast
agent in angiography, allowing imaging of choroidal and ret-
inal tissues.14–28 For ophthalmology, ICG is commercially
available under the names of ICG (Pulsion Medical Systems,
Munich, Germany; 25- and 50-mg vials), ICV Indocianina
Verde (Ophthalmos, São Paulo, Brazil; 5-, 25-, and 50-mg
vials), Diagnogreen (Daiichi Pharmaceutical, Tokyo, Japan;
25-mg vial), and IC-Green (Akorn, Buffalo Grove, USA; 25-
mg vial).
Infracyanine Green (IfCG) is a green dye with a chemical
formula and pharmacologic properties similar to those of
ICG. However, IfCG has a clear advantage over ICG because
it is synthesized without sodium iodine, as it is believed that
iodine damages the cornea and retina.29–31 On the other
hand, iodide-free IfCG is not water soluble and has to be dis-
solved in a 5% glucose solvent IfCG.32–34 It is commercially
available under the brand name of Infracyanine (Laboratoires
SERB, Paris, France; 25-mg vial).
Arylmethane dyes are stains which are formed by one car-
bon linked to benzene or naphthalene groups; they are com-
monly used in modern inks. BriB is a blue anionic arylmethane
compound which has the chemical formula of C47H48N3S2O7-
Na and a molecular weight of 854 Da. This dye was reported
to stain the ILM and to have no significant in vivo toxicity.23–26
The dye gained acceptance for intraocular use under the
brand name of Brilliant Peel (Geuder, Heidelberg, Germany),
and it is provided in vials containing 2 mg/ml of the vital dye.
Another example is Bromophenol blue (BroB) which is an
acid–base indicator that has recently been proposed as a
promising alternative biostain for vitrectomy, because it has
induced no damage in either in vitro or in vivo studies.15,16
It has a molecular weight of 670 Da and the chemical formula
is C19H10Br4O5S. PB is a hydrophilic anionic triarylmethane
dye with the chemical formula C27H31N2NaO6S2 and a
molecular weight of 582 Da. PB has been applied as an off-la-
bel agent in vitreoretinal surgery.
Xanthene is a yellow organic heterocyclic compound. Its
chemical formula is C13H10O. Xanthene dyes tend to be fluo-
rescent, yellow to pink to bluish red, brilliant dyes. Fluores-
cein is a xanthene fluorophore with the chemical structure
C20H12O5 and a molecular weight of 332 Da.
Corticosteroids are hormones produced naturally in the
cortex of the adrenal gland, whose derivates may be synthet-
ically produced to be used as drugs in the treatment of hu-man diseases. Triamcinolone acetonide (TA) is a synthetic
insoluble corticosteroid with the empirical formula
C24H31FO6 and a molecular weight of 434 Da. In ocular
surgery, TA has manifested a good staining of the vitreous
because of the crystal composition.Indications and toxicology
Indocyanine green
ICG facilitates ILM removal intraoperatively because it has
an affinity for extracellular matrix components of the ILM,
such as collagen and fibronectin.1–5 ICG had been used in
chromovitrectomy for macular hole treatment (Fig. 1).1–6,35–37
ICG has also been used to help ILM peeling in other dis-
eases, such as diabetic macular edema (DME). Consecutive
surgical experience determined that the use of ICG-assisted
ILM peeling in DME induced no sign of retinal toxicity by vi-
sual acuity measurements when comparing vitrectomy with
and without ILM peeling.38–41
Although the best indication for ICG use in chromovitrec-
tomy is for ILM staining in MH surgery, ICG has been pro-
posed for better visualization of epiretinal membranes
(ERMs) in vitrectomy for proliferative diabetic vitreoretinopa-
thy, idiopathic ERMs, and proliferative vitreoretinopathy
(PVR).42–44 However, the green dye may stain the acellular
ILM better; as for the task of ERM staining, other vital stains
may be better.
Regarding the toxicity of ICG, some investigators have re-
ported that the toxic effects of ICG are time and dose depen-
dent.45,46 However, Morales et al.47 indicated that the effects
of ICG are not strongly dose dependent, at least at the phys-
iological concentrations examined. ICG has been found to be
associated with the risk of damage to the photoreceptors
and RPE cells,48,49 atrophy of the retinal pigment epithelium
(RPE),50 loss of epiretinal cellular integrity,51 and cellular tox-
icity,52–55 among other harmful effects. In conclusion,
although much evidence suggests that ICG may exert toxic
effects on the retina, the staining agent in low doses should
be safe for chromovitrectomy.Infracyanine green
IfCG also binds with high affinity to the acellular ILM and
facilitates its visualization and peeling similar to ICG. It is
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and has reduced adverse effects.29–34,56 IfCG at a concentra-
tion of 0.5 mg/ml results in adequate ILM identification and
less toxic effects.57 No evidence of significant acute toxicity
is associated with IfCG.47 However, IfCG can be phagocy-
tosed by RPE cells, remaining in the interior of these cells
for long periods, with a risk of inducing chronic toxicity.34
Trypan blue
TB usage recommends blue dye application mainly for
ERM staining.9–12 TB exhibits outstanding affinity for ERM be-
cause of the strong presence of dead glial cells within those
membranes. I personally use it for immature PVR which may
minimize mechanical trauma to the retina during ERM re-
moval and allow the recognition of the whole extent of the
ERM. TB in various doses may enhance the ability to detect
both the prolapsed vitreous to the anterior chamber and
the posterior vitreous remaining in the vitreous cavity, but it
is inferior to TA.58 Regarding the chronic toxicity of TB, it
has been reported that it induces arrest of the cell cycle at
G0–G1 via increased expression of p21.59 Some researchers
showed that a subretinal injection of 0.05% ICG results in a
more substantial retinal damage than that associated with
subretinal injection of 0.15% TB.57
Brilliant blue
BriB has been introduced as a surgical adjuvant for chro-
movitrectomy in 2006 and, this dye was reported to stain
the ILM and to have no significant in vivo toxicity.23,24 Cerve-
ra et al.60 showed similar outcomes with good ILM staining
and clinical results and no signs of toxicity in multifocal
ERG. BBG is more hydrosoluble than ICG and IfCG; it would
thus penetrate less into the cells and be more easily washed
away, leaving less residues after surgery.47 For this reason,
BriB represents a good alternative for ICG and IfCG in chro-
movitrectomy due to its suitable affinity for ILM (Fig. 2).
Patent blue
The utility of the PB dye for applications in ophthalmology
has only recently been discovered, and relatively little is
known about its effects. For this reason, the present findings
are of particular interest.47 It has a moderate affinity for ERMFigure 2. Brilliant blue is an excellent tool in optimizing internal limiting
membrane peeling which enables a clear distinction between the
unstained retina and the stained overlying fine ILM tissue.and vitreous, but a poor affinity for the ILM.17 PB affects
human retinal function when applied for at least 1 min. How-
ever, no irreversible effects on the human ERG were seen
even after 2 min of retinal exposure to patent blue. Thus,
toxic effects on retinal function after intraoperative short-
term application of patent blue 0.48% appear unlikely to
occur.18 Subretinal injection of TB induced a more significant
clinical and histologic damage of neurosensory retina/RPE
than did PB or Balanced Salt Solution (BSS).19
Bromophenol blue
BroB has been applied in ocular surgery: the dark-blue
stain may represent a novel useful adjunct for both cataract
and vitreoretinal surgery. BroB stained the retinal surface
and lens capsule at a low concentration (0.2%) with no signs
of toxicity, this dye seems to be the most promising candi-
date for application in humans.15 Schuettauf et al.16 demon-
strated that BroB dye tested in his study did not lead to
detectable toxic effects in the rat eye, even after prolonged
presence within the eye and an observation period of 7 days.
Other novel dyes as well as ICG showed toxic effects, such as
histologic alteration of the retina and loss of RGCs.
Sodium fluorescein
SF is highly safe for fundus angiography at concentrations
of 5–25%. The intravitreal 0.20% SF dye improves the visual-
ization of clear vitreous fibers through a green staining during
chromovitrectomy. The clear vitreous can be stained mark-
edly green by SF administered 12–16 h before surgery.61 A
preoperative diagnostic fluorescein angiography in eyes with
active uveitis or diabetic retinopathy may lead to a moderate
accumulation of the dye in the vitreous cavity and greenish
staining of the vitreous cortex at the vitreoretinal inter-
face.62,63 SF 0.6% can safely be used in the vitreous cavity
for easy identification of clear uncut vitreous gel for clear vit-
reous vitrectomy. This enhances efficient excision of this
tissue.64
Triamcinolone acetonide
TA produces the best vitreous visibility in comparison to
other stains.65 The crystals of the steroid adhere to the acel-
lular tissue, thereby enabling a clear contrast between the
empty vitreous cavity compared to areas with the vitreous fi-
bers remaining.66 The surgical technique for TA application
consists of a direct injection of the agent into the vitreous
cavity toward the area of interest. TA-assisted removal of
internal limiting membrane was used in many cases since
the white specks and crystals may deposit over the ILM,
thereby facilitating ILM removal (Fig. 3).67,68 Crystals of TA
have been detected up to 40 days postsurgery with chromo-
vitrectomy for MH surgery. For this reason, some authors
suggest that postoperative residual TA could diminish the
healing process necessary for MH closure.69 Injecting this
steroid during vitrectomy for the management of retinal
detachment may prevent fibrin reaction and PVR postopera-
tively.70–72 The commonly used formulation of TA, kenalog, is
not formulated for the eye, for this reason, there is a risk of
pseudoendothalmitis and retina toxicity when injected
intravitreally.73,74 There have been reports of toxicity of TA
Figure 3. The steroid triamcinolone acetonide (TA) stains the vitreous
powerfully and by that means ensures that the whole posterior vitreous
cortex is removed during surgery.
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ex vivo and in vivo studies have not shown any significant tox-
icity on the retina.76
Vital dyes and light sources
Interaction of light from endoillumination source and vital
dye may increase or decrease the risk for toxicity. Light-in-
duced retinal toxicity by the endoilluminator is dependent
on factors such as the duration of use, type, power, and
wavelength of light source.77,78 Vital dyes are small chemical
substances that pass freely through retinal tissue and may
play a role in or exacerbate retinal phototoxicity from intra-
operative light exposure.79 Photosensitizing dyes could en-
hance phototoxicity by increasing levels of free radicals,
creating a photoproduct that could be harmful to retinal cells
and shifting light absorbance from one site of the retina to
another.79 In this regard, the dye on the retinal surface could
increase the risk for phototoxicity to the neuroretina for light
greater than 450 nm, which would not occur without dyes.80
In addition, dyes in the subretinal space may exacerbate
damage to the RPE after exposure to various wavelengths
of light.81 From a surgery perspective, among all light
sources analyzed by Costa et al.79, the greatest overlap was
found with integrated laser pathway (Photon Xenon; Syner-
getics Photon) and halogen (Grieshaber GLS; GLS Corp.),
and the least overlap was found with mercury vapor lamp
(Photon 2; Synergetics). The lowest overlap values among
the dyes were observed with ICG prepared in PSS, followed
by IC, which showed low values for all three solvents com-
pared with other dyes.
Dye injection techniques
There are different ways to protect the RPE cells during
dye injection in the MH surgery: slow injection of the dye,
placing substances over the MH such as sodium hyaluro-
nate.82 perflourocarbons liquids (PFCL),83 autologous whole
blood84, or use of VINCE (vitreoretinal internal limiting mem-
brance color enhancer) which enables selective painting of
ILM that needs to be removed without staining perifoveal
and peripheral retinae.85 The most common two ways in
dye injection technique are:
1. The ‘‘dry method’’ or ‘‘air-filled technique’’. This tech-
nique consists of removing the fluid in the vitreous cavity
by a fluid-gas exchange before dye injection.85 While thetechnique has the advantage of concentrating the dye in
the posterior pole and avoiding contact at the posterior
capsule of the lens, it may expose the retinal surface to
a higher concentration of dye to the vitreoretinal
interface.5
2. The ‘‘wet method’’ or ‘‘fluid-filled technique.’’ In this
approach, the intravitreal fluid (usually balanced salt solu-
tion) is left inside the vitreous cavity, while the surgeon
injects the dye. The amount of dye in contact with the ret-
inal surface becomes much lower because it is immedi-
ately washed out by the fluid in the vitreous cavity.87
Czajka et al. compared the two methods in a porcine
model and concluded that the air-filled technique induces
a higher incidence of RPE atrophy and outer retinal
degeneration than the fluid-filled technique.86 In conclu-
sion, the wet method is more safer and faster during sur-
gery than dry method.
Conclusion
Exploration of the breakthrough chromovitrectomy sup-
ports innovative microsurgical techniques with improved pa-
tient outcomes for both anterior and posterior segment
procedures. Recent recommendations for the application of
dyes during vitreoretinal surgery designate that ICG, IfCG,
BriB, and BroB may be the best stains for ILM, while TB
and PB may be preferred for staining the glial ERM. In addi-
tion, the white steroid TA is an amazing staining agent for vit-
reous visualization. Regarding to the toxicity issues, no
decided safety profiles for the different dyes in chromovitrec-
tomy. In addition, some good words include avoidance of
long macular exposure to endoillumination and, low amount
of dye injection.Conflict of interest
The authors declared that there is no conflict of interest.References
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